The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
The role of stromal cells and the tumour microenvironment in general in modulating tumour sensitivity is increasingly becoming a key consideration for the development of active anticancer therapeutics. Here, we discuss how these tumour-stromal interactions affect tumour cell signalling, survival, proliferation and drug sensitivity. Particular emphasis is placed on the ability of stromal cells to confer - to tumour cells - resistance or sensitization to different classes of therapeutics, depending on the specific microenvironmental context. The mechanistic understanding of these microenvironmental interactions can influence the evaluation and selection of candidate agents for various cancers, in both the primary site as well as the metastatic setting. Progress in in vitro screening platforms as well as orthotopic and 'orthometastatic' xenograft mouse models has enabled comprehensive characterization of the impact of the tumour microenvironment on therapeutic efficacy. These recent advances can hopefully bridge the gap between preclinical studies and clinical trials of anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“There is increasing evidence that the activated stroma is a disease-de fi ning factor, highlighting it as an important player in cancer cell invasion/extravasation, migration, angiogenesis, drug resistance [6,7], cancer stem cell maintenance [8], and immunosurveillance evasion [6,9,10].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [6]
In the citing paper
“Hence, tumor-stromal interactions, the composition of the TME and tumor immune status all contribute to determining tumor growth, metastasis, angiogenesis and therapy resistance (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021), thereby critically influencing the clinical outcome of cancer patients.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“In addition, many studies have highlighted the critical importance of the microenvironment for promoting or suppressing tumor growth, invasion, metastasis, and response to therapy (McMillin et al., 2013; Fontana et al., 2021; Rodrigues et al., 2021; Xiao and Yu, 2021).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as McMillin et al., 2013
In the citing paper
“The non‐malignant cells and matrixcomponents which make up the TME have been shown to playa role in tumor cell survival, proliferation,andtreatment resistance (48).”
From Resistance Mechanisms and Approach to Chronic Lymphocytic Leukemia after BTK Inhibitor Therapy (2025) · cites this paper as [48]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Cited by
Items 401–491 of 491
Cytokine Therapy in the Tumor Microenvironment
Ganß, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804214-4.00013-0 · Cited by 1
Fibroblasts modulate the tumor cell motility and their mTOR/S6K1 phosphorylation status in vitro
Hotsuliak, N. Y., Kosach, V., Tykhonkova, I. O., Palchevskii, S. S., & Хоруженко, А. І. (2019) · Biopolymers and Cell · doi:10.7124/bc.000a15 · Cited by 1
Rencüzoğulları, Ö., Ozfiliz-Kilbas, P., Bal, E., & Ayhan‐Sahin, B. (2023) · Biochemistry · doi:10.5772/intechopen.113859 · Cited by 1
Chitre, S., Huang, H. J., & Xu, Y. (2025) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.894 · Cited by 1
Elton, E., Tavakoli, N., Çetin, H., & Finley, S. D. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-026-00673-8 · Cited by 2
“Already, drug dis-coveryinvestigationsareconsideringtheimpactofcomponentsoftheTMEondrugresponse 45,46 .”
The Role of One‐Carbon Metabolism in Cancer and Its Therapeutic Significance
Jiang, Y., Zhou, G., Zhang, Q., & Zhou, S. (2026) · MedComm – Oncology · doi:10.1002/mog2.70062 · Cited by 2
Recent advances in purpose-built 3D bioprinted cancer models for drug development
Ramos, L., Robinson, M., Lallous, N., Flannigan, R. K., & Daugaard, M. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2642320 · Cited by 1
“Therefore, mimicking native tumor-stroma cytoarchitecture is an important consideration to capturing cancer cell behaviors and drug sensitivities in vitro [27].”
Transmembrane lectins in cancer immunity: emerging drivers of myeloid-mediated immunosuppression
Trindade, G., Palma, A. S., & Brito, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1952520 · Cited by 2
Sun, Y., & Chiao, P. J. (2017) · InTech eBooks · doi:10.5772/66575 · Cited by 1
“As an efficient growth stimulator, IL-6 enhances resistance by counteracting chemotherapy and hormone therapy of multiple myeloma; it is also a therapeutic target in Castleman’s disease and several epithelial malignancies including mammary, breast ovarian, prostate cancers [77].”
Evans, D. M., & Teicher, B. A. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57424-0_19 · Cited by 1
Gerashchenko, G. V., Vagina, I. M., Vagin, Y. V., & Kashuba, V. I. (2020) · The Ukrainian Biochemical Journal · doi:10.15407/ubj92.01.005 · Cited by 1
Neuregulin Signaling in the Tumor Microenvironment
Jia, R., Zhao, H., & Wang, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-47189-7_1 · Cited by 2
ASO Author Reflections: Organoid-Based Precision Medicine in Colorectal Cancer—Are We There Yet?
Flood, M. P., Ramsay, R. G., & Heriot, A. G. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10831-3 · Cited by 1
Smith, P. J., Griesdoorn, V., Silvestre, Ó. F., & Errington, R. J. (2017) · Series in bioengineering · doi:10.1007/978-981-10-4499-1_1 · Cited by 1
Stromal Cells and Extracellular Vesicles
Ude, A., Ogbodo, E., & Okeke, K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106721 · Cited by 1
Lego‐Inspired Splicing of Modularized Vascular Channels
Zou, X., Zhu, S., Xia, Y., Gao, J., Chen, J., Yao, P., Ye, M., Shen, S., & Xu, R. X. (2025) · Small Methods · doi:10.1002/smtd.202401928 · Cited by 1
A cross-talk network that facilitates tumor virotherapy
Bronisz, A., & Chiocca, E. A. (2015) · Nature Medicine · doi:10.1038/nm.3857 · Cited by 1
Preclinical Cancer Models with the Potential to Predict Clinical Response
Scherzer, M., Kramer, N., Unger, C., Walzl, A., Walter, S., Stadler, M., Hengstschläger, M., & Dolznig, H. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802208-5.00004-7 · Cited by 1
The Emerging Role of Exosomes in Cancer Progression and Their Potential as Therapy Targets
Ruivo, C. F., & Melo, S. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-71553-7_3 · Cited by 1
Decellularized Matrix Hydrogels for In Vitro Disease Modeling
Ferreira, L. P., Monteiro, M. V., Gaspar, V. M., & Mano, J. F. (2021) · Royal Society of Chemistry eBooks · doi:10.1039/9781839161124-00626 · Cited by 2
3D Bioprinting in Oral and Maxillofacial Surgery
Tayebi, L., Masaeli, R., & Zandsalimi, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-77787-6_3 · Cited by 1
Dias, M. P., Rottenberg, S., & Jonkers, J. (2022) · STAR Protocols · doi:10.1016/j.xpro.2022.101132 · Cited by 1
“This prevents screening for factors involved in tumor microenvironment interactions, which has been found to influence treatment response in breast cancer (reviewed in Mcmillin et al., 2013).”
BackgroundRole of Tumour-Associated Macrophages in Colon Cancer Progression and Its Therapeutic Targeting
Mehta, A., Soni, V. K., Ratre, Y. K., Amit, A., Shukla, D., Kumar, A., & Vishvakarma, N. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-72702-4_10 · Cited by 1
Role of tumor microenvironment in prostate cancer therapy resistance
Malak, L. A., Souki, M. S. A., Moubayed, I., Ghamlouche, F., & Abou-Kheir, W. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-16032-5.00014-2 · Cited by 1
Drug resistance in recurrent and metastatic Ewing sarcomaPreprint
Zhang, L., & Yu, Y. (2021) · doi:10.22541/au.163476822.21319119/v1 · Cited by 1
Intravital Microscopy for Molecular Imaging in Cancer Research
Yu, H., & Gambhir, S. S. (2014) · Springer eBooks · doi:10.1007/978-94-017-9361-2_12
The Role of Exosomes and its Cargos in Drug Resistance of Cancer
Xie, Y., & Fu, L. (2015) · Journal of cancer research updates · doi:10.6000/1929-2279.2015.04.04.6
Roles of the ING1 Epigenetic Regulator in Breast Cancer
Thakur, S. S. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27691
Size Matters: Developing Design Rules to Engineer Nanoparticles for Solid Tumour Targeting
Sykes, E. A. (2015) · TSpace (University of Toronto)
Manem, V. S., Adam, G. A., Gruosso, T., Gigoux, M., Bertos, N., Park, M., & Haibe‐Kains, B. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/102848
“Many clinical and biological studies have supported the role of diverse paracrine, autocrine, and endocrine signaling interactions in the tumor ecosystem [3] .”
BackgroundVeloso, S. C. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Uncoupling tumor-stroma interactions in breast cancer patients
Sourbier, C., & Neckers, L. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.10.008
Wagner, F. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.116423
Cadavid-Vargas, J. F. (2019) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/73701 · Cited by 2
Développement d'approches d'imagerie multimodale pour la recherche en oncologie
Lavaud, J. (2018) · theses.fr (ABES) · doi:10.70675/44a63bf2z3eafz4346z906bzc81b957d2fd8
Irreversible Electroporation: Expanding the Armamentarium against Pancreatic Cancer
Lyons, G. R., Schiro, B. J., & Narayanan, G. (2019) · Digestive Disease Interventions · doi:10.1055/s-0039-1693226
Kumar, D., Sharma, P. K., & Malviya, R. (2020) · Nanoscience & Nanotechnology-Asia · doi:10.2174/2210681210666200108125840 · Cited by 1
Biofabricated three-dimensional tissue models
Berry, D. B., Yu, C., & Chen, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00077-0
Advance in Pancreatic Cancer Diagnosis and Therapy
Cai, X., Gao, J., Liu, Y., Wang, M., Ma, Q., Gong, A., Wang, D., & Zhu, H. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94413
Cell cultures of human malignant tumors in development of new anticancer therapies
Chernov, A. N., Barantsevich, E. P., Галимова, Э. С., & Galagudza, M. M. (2018) · Nauchno-prakticheskii zhurnal «Patogenez» · doi:10.25557/gm.2018.4.9744
RIP1 is Novel Component of γ-Ionizing Radiation-Induced Invasion of Non-Small Cell Lung Cancer CellsPreprint
Cho, J., Kang, A.-R., Lee, N.-G., Song, J. Y., Hwang, S., Lee, D.-H., Um, H., & Park, J. K. (2020) · Preprints.org · doi:10.20944/preprints202001.0252.v1
Kort-Mascort, J. (2019) · eScholarship@McGill (McGill) · doi:10.82308/41596 · Cited by 1
Tumor cell-derived CCL2 promotes chemoresistance via c-Fos in lung adenocarcinomaPreprint
Wang, D., Yang, L., Li, Y., Cao, L., Zhang, K., Lian, J., Shen, Z., Huang, J., Wang, L., & Zhang, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-450308/v1
“One of the main causes of treatment failure in cancer patients is resistance to chemotherapy [1, 2].”
BackgroundA critique. B. F. Skinner's behaviorism.
Dunning, R. (1972) · PubMed
Vaithilingam, V., Reys, L. L., Sthijns, M. M. J. P. E., Rademakers, T., de Vries, R. H. W., Mohammed, S. G., Bont, D. D., Jetten, M., de Koning, E. J. P., Mourad, N. I., et al. (2022) · Tissue Engineering Part A · doi:10.1089/ten.tea.2022.29025.abstracts
Muehlich, S., & Mittermeier, C. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732604703.793545061
Manem, V. S., Adam, G. A., Gruosso, T., Gigoux, M., Bertos, N., Park, M., & Haibe‐Kains, B. (2023) · doi:10.1158/0008-5472.22418180
Peña, C. M., Lee, A. H., Frare, M. F., Ghosh, D., & Dawson, M. (2023) · Current cancer research · doi:10.1007/978-3-031-22802-5_4 · Cited by 1
Rondeau, E. (2021) · theses.fr (ABES) · doi:10.70675/6e037beazf15ez47c5z9490z55191ed1ca1f · Cited by 3
Pradat, Y. (2024) · theses.fr (ABES) · doi:10.70675/aa9a9c8czf5fdz465fz89e5zd8de2f37b01f · Cited by 1
Zhu, M., Li, X., Xu, C. W., Yi, X., Ye, F., Li, X., Hu, Z., Zhang, L., Nie, J. J., & Li, X. (2022) · Figshare · doi:10.6084/m9.figshare.19738555
Zhu, M., Li, X., Xu, C. W., Yi, X., Ye, F., Li, X., Hu, Z., Zhang, L., Nie, J. J., & Li, X. (2022) · Figshare · doi:10.6084/m9.figshare.19738552
Pharmacological cancer research using cancer cell line-derived xenograft (CDX) mouse models
Tsumura, R., & Takashima, H. (2024) · Drug Delivery System · doi:10.2745/dds.39.192
Varga-Zsíros, V. (2024) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.12120
Advancing In Vitro Tools for Oncologic Research in Cats and Dogs
He, C., & Rottenberg, S. (2025) · Veterinary Sciences · doi:10.3390/vetsci12090815
“This limitation likely contributes to the observed discrepancies in drug sensitivities between in vitro and in vivo mouse mammary tumor models, due to the protective effects of the tumor microenvironment [126,127].”
Zhao, Y., Weng, Z., Zhou, X., Xu, Z., Cao, B., Wang, B., & Li, J. (2024) · Figshare · doi:10.6084/m9.figshare.26577710
Zhu, M., Li, X., Cheng, X., Yi, X., Ye, F., Li, X., Hu, Z., Zhang, L., Nie, J. J., & Li, X. (2022) · Figshare · doi:10.6084/m9.figshare.19738558
Zhao, Y., Weng, Z., Zhou, X., Xu, Z., Cao, B., Wang, B., & Li, J. (2024) · Figshare · doi:10.6084/m9.figshare.26577713
Mehta, V., Vilikkathala Sudhakaran, S., Nellore, V., Madduri, S., & Rath, S. N. (2024) · Figshare · doi:10.6084/m9.figshare.26736153
del Barrio, I. M. (2015) · Online Publication Service of Würzburg University (Würzburg University)
Akar, B. (2024) · eArsiv - Adu (Adnan Menderes University)
Hußtegge, M. (2024) · Qucosa (Saxon State and University Library Dresden)
Brown, L. (2026) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33890359
Construction and immunotherapy application of lung cancer organoids
Li, W., Ge, Y., Zhang, Z., Gan, J., Yao, W., Jin, Y., Bi, Y., & Sun, G. (2026) · International Journal of Cancer · doi:10.1002/ijc.70347 · Cited by 2
“45,46 In particular, the TME of lung cancer is a highly complex and dynamic ecosystem containing multiple immune cells, cytokines, chemokines, and tumor cells themselves, involving multiple cell types, signaling pathways, and their interactions (Figure 4).”
ELDA: real-time functional drug profiling in acute lymphoblastic leukemia
Mariano, S. D. S., Assis, L. H. D. P., Corrêa, J. R., Canevarolo, R. R., Migita, N. A., Sudalagunta, P. R., de Azevedo, A. C., Meidânis, J., Brandalise, S. R., Silva, A. S., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1685447
“AIM-V is a nutrient-rich medium formulation based on DMEM and Ham ’ s F12, enriched with human serum albumin, insulin, transferrin, and a blend of puri fi ed non-cytokine factors (44).”
Microparticles Mediated Cross-Talk Between Tumoral And Endothelial Cells
Al-Thawadi, H. (2015) · theses.fr (ABES) · doi:10.70675/9c5b9092z11fcz4187zb973z8dcd2724a4de
Le microenvironnement immunitaire des Carcinomes épidermoides de la cavité orale
Rochefort, J. (2017) · theses.fr (ABES) · doi:10.70675/0321de6bzbd5bz4b7az96c5z0a2e43543020 · Cited by 1
Sadacca, B. (2017) · theses.fr (ABES) · doi:10.70675/86d0b41azfb6bz44bdz9f35zf24452ba9c6a
Tissu adipeux et résistance tumorale aux thérapies ciblées
Geneste, A. (2018) · theses.fr (ABES) · doi:10.70675/1521e85cz8c2fz4c73za577z0f6537a4e8de · Cited by 1
Pinheiro, A. M. (2019) · theses.fr (ABES) · doi:10.70675/e234e25ez93ddz48d8z94daz0ebd0e211314
Goisnard, A. (2021) · theses.fr (ABES) · doi:10.70675/efb6e253zbfeaz431aza15czc11449d801f3
Dhungel, N., Latimer, B., Custis, D., & Dragoi, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.721078
“It has been shown that tumors resistant to alkylating agents in vivo become sensitive to the same agents when cultured outside the body in the absence of their TME, indicating that stromal cells may contribute to the development of resistance to anticancer drugs [18, 19].”
New insights in tumor-on-a-chip models for studying cancer drug resistance
Wang, Y., Shi, L., Li, J., Zhang, X., Ren, J., Jia, Q., Lv, L., Yang, L., Zhang, Z., Yang, J., et al. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156562
We designed a new way to build miniature fluidic devices to enable personalized cancer treatment
Tamrin, S. H., & Sen, A. (2026) · The Conversation · doi:10.64628/aam.cnvahcwr7
Nous avons mis au point un nouveau dispositif pour un traitement personnalisé du cancer
Tamrin, S. H., & Sen, A. (2026) · The Conversation · doi:10.64628/aap.9nutacyt6
Malik, G., Bashir, S., Javeed, S., Dhanawat, M., & Girdhar, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33206-7.00008-x
EXTRACELLULAR MATRIX AND TUMOR MICROENVIRONMENT: ROLE OF EXTRACELLULAR VESICLES
Tassinari, S. (n.d.) · Institutional Research Information System University of Turin (University of Turin)
Rational design of drug combinations for the chemoprevention of hereditary diffuse gastric cancer
Redpath, K. (2025) · Otago University Research Archive (University of Otago) · Cited by 1
Metadata
- Authors
- McMillin, D. W., Negri, J. M., & Mitsiades, C. S.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Harvard University (US)
- Corresponding author
- Mitsiades, Constantine S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2013-03
- Volume
- 12
- Issue
- 3
- Pages
- 217-228
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1980669422
- Cited by
- 474
- References
- 150
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 27 · 2023: 34 · 2022: 29 · 2021: 43 · 2020: 41 · 2019: 33 · 2018: 49 · 2017: 56 · 2016: 41 · 2015: 40 · 2014: 27 · 2013: 16
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R0-1 50947)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- tumor microenvironment, stromal cells, drug resistance, drug sensitivity, anticancer drug discovery, preclinical models, orthotopic xenograft, metastasis
- MeSH terms
- Animals, Antineoplastic Agents, Drug Evaluation, Preclinical, Drug Screening Assays, Antitumor, Humans, Neoplasms, Stromal Cells, Drug Resistance, Neoplasm, Drug Discovery, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.